| Hepatocellular Carcinoma |
1 |
1 |
| Liver |
0 |
0.74 |
| Biliary Disease |
0 |
0.6 |
| Hepatic Surgery |
0 |
0.49 |
| Biologic Therapy |
0 |
0.46 |
| Neoadjuvant Therapy |
0 |
0.45 |
| Tyrosine Kinase Inhibitor |
0 |
0.35 |
| Cancer |
0 |
0.33 |
| Tyrosine Kinase |
0 |
0.25 |
| Toxicology |
0 |
0.2 |
| Meta-Analysis |
0 |
0.17 |
| Thromboembolism |
0 |
0.13 |
| Adjuvant Chemotherapy |
0 |
0.12 |
| Ablation |
0 |
0.08 |
| Angiogenesis Inhibitors |
0 |
0.08 |
| Chemotherapy |
0 |
0.08 |
| Cirrhosis |
0 |
0.08 |
| Clinical Research |
0 |
0.08 |
| Disability |
0 |
0.08 |
| Embolization |
0 |
0.08 |
| Humanized Monoclonal Antibody |
0 |
0.08 |
| Postoperative |
0 |
0.08 |
| Preoperative |
0 |
0.08 |
| Surgery |
0 |
0.08 |
| Surgical Complication |
0 |
0.08 |
| Transplant Evaluation |
0 |
0.08 |
| Tumor |
0 |
0.08 |
| Healthcare and Medical Technology |
0 |
0.07 |